Author contributions
Aswanth Reddy contributed to the preparation of the manuscript, writing the initial draft, and finalizing the final draft. The author has given final approval for the version to be published. The author agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part are appropriately investigated and resolved.
Nkolika Nwankwo contributed to the preparation of the manuscript, writing the initial draft, and finalizing the final draft. The author has given final approval for the version to be published. The author agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part are appropriately investigated and resolved.
Arjun Sekar contributed to the preparation of the manuscript, writing the initial draft, and finalizing the final draft. The author has given final approval for the version to be published. The author agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part are appropriately investigated and resolved.
Aswini Kumar contributed to the preparation of the manuscript, writing the initial draft, and finalizing the final draft. The author has given final approval for the version to be published. The author agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part are appropriately investigated and resolved.
References
1. Schiller LR, Pardi DS, Sellin JH. Chronic Diarrhea: Diagnosis and Management. Clin Gastroenterol Hepatol. 2017 Feb;15(2):182-193.e3.
2. Burgers K, Lindberg B, Bevis ZJ. Chronic Diarrhea in Adults: Evaluation and Differential Diagnosis. Am Fam Physician. 2020 Apr 15;101(8):472-480.
3. Gómez-Escudero O, Remes-Troche JM. Approach to the adult patient with chronic diarrhea: A literature review. Rev Gastroenterol Mex (Engl Ed). 2021 Oct-Dec;86(4):387-402.
4. Camilleri M, Sellin JH, Barrett KE. Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea. Gastroenterology. 2017 Feb;152(3):515-532.e2.
5. Thielman NM, Guerrant RL. Clinical practice. Acute infectious diarrhea. N Engl J Med. 2004 Jan 1;350(1):38-47.
6. Wells SA Jr, Asa SL, Dralle H et al. American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610.
7. Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer. Oncologist. 2013;18(10):1093-100.
8. Chen H, Sippel RS, O’Dorisio MS et al. North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010 Aug;39(6):775-83.
9. Thomas CM, Asa SL, Ezzat S et al. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines. Curr Oncol. 2019 Oct;26(5):338-344.
10. Pellegriti G, Leboulleux S, Baudin E et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer. 2003 May 19;88(10):1537-42.
11. Pacini F, Castagna MG, Brilli L et al. ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v214-9.
12. Pusztaszeri MP, Bongiovanni M, Faquin WC. Update on the cytologic and molecular features of medullary thyroid carcinoma. Adv Anat Pathol. 2014 Jan;21(1):26-35.
13. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005 Apr;90(4):2029-34.
14. Tran K, Khan S, Taghizadehasl M et al. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Hell J Nucl Med. 2015 Jan-Apr;18(1):19-24.
15. Ciampi R, Romei C, Ramone T et al. Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. iScience. 2019 Oct 25;20:324-336.
16. Wells SA Jr, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Erratum in: J Clin Oncol. 2013 Aug 20;31(24):3049.
17. Elisei R, Schlumberger MJ, Müller SP et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864.
18. Schlumberger M, Jarzab B, Cabanillas ME et al. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 1;22(1):44-53.
19. Wirth LJ, Sherman E, Robinson B et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27;383(9):825-835.
20. Subbiah V, Hu MI, Wirth LJ et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. doi: 10.1016/S2213-8587(21)00120-0. Epub 2021 Jun 9. Erratum in: Lancet Diabetes Endocrinol. 2021 Oct;9(10):e4.
21.Pais MC, Maia T, Peixoto A et al. Diarrhea as a form of presentation of medullary thyroid carcinoma. Porto Biomed J. 2018 Jul 3;3(3):e18.